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Internalisation of the mu opioid receptor from the surface of cells is generally achieved 
by receptor occupancy with agonist ligands of high efficacy. However, in many 
situations the potent analgesic morphine fails to promote internalisation effectively and 
whether there is a direct link between this and the propensity for the sustained use of 
morphine to result in both tolerance and dependence has been studied intensely. 
Although frequently described as a partial agonist, this characteristic appears 
insufficient to explain the poor capacity of morphine to promote internalisation of the 
mu opioid receptor. Experiments performed using both transfected cell systems and ex 
vivo/in vivo models have provided evidence that when morphine can promote 
internalisation of the mu receptor there is a decrease in the development of tolerance 
and dependence. Although aspects of this model are controversial, such observations 
suggest a number of approaches to further enhance the use of morphine as an analgesic. 
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Introduction 
Opiates and endogenous enkephalin neuropeptides perform their physiological actions by 
interacting with four different receptor subtypes, namely mu, delta, kappa and nociceptin 
receptors, belonging to the superfamily of G protein-coupled receptors [1]. G protein-coupled 
receptors or GPCRs are polypeptide proteins that cross the cellular lipidic bilayer via seven 
transmembrane domains enriched in hydrophobic amino acids. The central function of 
GPCRs is to transmit information from the extracellular face of the plasma membrane to 
within cells by coupling with heterotrimeric G proteins, another family of cell membrane 
proteins. The interaction between a receptor-G protein pair is promoted by the selective 
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binding of chemical compounds named agonists that generate specific conformational 
changes in the receptor. After coupling with a GPCR, Gα subunits of G proteins exchange 
GDP for GTP and may dissociate from their associated Gβγ dimeric subunits, initiating from 
each component diverse intracellular signalling cascades via activation of a variety of 
effectors including, amongst others, adenylyl cyclases, phospholipases and gated ion channel 
receptors. 
Morphine, and chemical derivates of this alkaloid, are drugs widely known for their potent 
analgesic properties in clinical practice as well as for their recreational use.  In general, these 
drugs bind preferentially to mu opioid receptors. In fact, the designation “mu” was originated 
when it was observed that morphine selectively discriminated this receptor from the other 
opioid receptor subtypes [1]. More recently, the development and phenotypic characterisation 
of genetically modified animals lacking expression of mu opioid receptors finally confirmed 
that morphine exerts both its analgesic and antinociceptive actions through this receptor in 
living organisms [2]. Although morphine is considered one of the most potent analgesic 
drugs, especially for the treatment of chronic or refractory pain, its use in clinical practice is 
limited by the occurrence of tolerance and dependence following prolonged treatment [3].  
Tolerance is defined as a diminishment in the effect of a drug such that larger doses are 
necessary to produce the initial effect(s). This augmentation of the drug dose required for 
effect facilitates the development of undesired side effects that, in the case of morphine, may 
include constipation or respiratory depression. Dependence is related to neuronal changes at 
both the cellular level and in synaptic organisation that generate physical symptoms following 
withdrawal of the drug [4, 5].  The fact that not all opioid drugs generate the same degree of 
tolerance and dependence in experimental animals when they are administered chronically at 
equi-effective analgesic doses led to consideration that different effects must be produced at 
the molecular and cellular level when these agonists bind to mu receptors.  
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 The development of recombinant cDNA methodology, combined with a wide range of 
molecular and cell biology techniques, made possible the expression of particular genes of 
interest in diverse host cells. Such heterologous expression systems have been extremely 
useful in investigations of events that occur at the cellular level when a GPCR is activated by 
a specific agonist. Although initially investigations were focussed predominantly on the β2-
adrenoceptor, many of the effects observed for this GPCR have been corroborated 
subsequently for other GPCR family members and have provided a series of paradigms that 
define key molecular process that occur following receptor activation [6]. Essentially these 
models postulate that the interaction of an agonist-occupied GPCR with a G protein is 
interrupted by the phosphorylation of the receptor by specific GPCR kinases or GRKs. This 
defines that the phosphorylated receptor is more prone to recruit and interact with arrestins 
than the native state of the receptor. As well as binding directly to GPCRs, the arrestins are 
cytosolic proteins that operate as scaffolding elements in different cell signalling processes 
and also facilitate the internalisation of GPCRs, as well as other classes of transmembrane 
receptors, by recruiting proteins involved in the endocytic machinery, such as clathrin and the 
AP-2 adapter complex, to form finally an endocytic vesicle. The participation of the GTPase 
dynamin allows the vesicle to be pinched off from the external membrane. The fate of such 
endosomes, containing the receptor, is non-uniform; in some cases endosomes merge to 
eventually form lysosomes that degrade proteins within them. By contrast, in other situations, 
endosomes are recycled to the plasma membrane, where dephosphorylated GPCRs are 
refreshed to a state able to interact productively yet again with agonist, re-initiating cellular 
signalling processes [7]. Regardless of the endocytic pathway followed by the endosomes, it 
can be considered as a general situation that continual stimulation of a receptor by constant 
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exposure to many agonist drugs results in a reduction of the receptor number in the plasma 
membrane and within the cell. These processes are known collectively as down-regulation. 
 
In pharmacology, the term desensitisation refers to the loss of responsiveness of the assessed 
system to the continuing presence of a drug.  From a molecular point of view, and in the case 
of GPCRs, this desensitisation takes place initially when the receptor is phosphorylated and, 
as a result of this and enhanced interaction with an arrestin, interaction with G-protein is 
interrupted. The desensitisation of a GPCR is designated as homologous or heterologous 
dependent on the nature of the protein kinase involved in the phosphorylation event(s) and 
whether the effect is manifest only on the receptor activated by the agonist [6]. Homologous 
desensitisation generally occurs when the receptor is activated by a specific agonist and a 
GRK is involved, whereas heterologous desensitisation refers to the participation of other 
kinases, e.g. Protein Kinase A or Protein Kinase C, that are activated by specific interacellular 
secondary messengers, not necessarily generated by the same receptor that becomes 
phosphorylated. In addition, down-regulation of the total cellular content of a receptor 
following endocytosis can be considered as another, longer term, mechanism of generating 
desensitisation. Equivalently, the process of recycling receptor-containing endosomes to the 
plasma membrane, where the receptor can be activated again by agonist, is known as 
resensitisation.  Therefore, the concept of desensitisation in reference to receptor function 
may be equivalent to tolerance at the physiological level. 
 
Morphine is distinct when compared to many other agonist drugs that bind to and activate the 
mu opioid receptor because of a noted accentuated capacity to generate tolerance and 
dependence when used in long-term treatments. The molecular and cellular basis of this 
particular feature has been the object of many studies during the last decade, which have 
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resulted in a plethora of concepts and hypotheses, and remains a matter of considerable 
conjecture and debate [8-13]. In this review we compile information on several of the 
approaches and studies that have provided some insight in the basis of this characteristic 
pharmacological event. 
 
The cloning of cDNA encoding for species orthologues of the mu and other opioid receptors 
in the early 1990s [1] permitted these receptors to be expressed either transiently or stably in 
heterologous systems, including transformed mammalian cell lines. As noted earlier, such 
experimental cell models have been extremely useful to complete the pharmacological 
characterisation, in terms of drug selectivity as well as agonist efficacies and potencies, of 
each opioid receptor subtype when expressed individually. Furthermore, such experimental 
models have allowed genetically modified receptors, for example containing a short amino 
acid sequence as an epitope that is recognised specifically by an antibody, to be expressed and 
studied. The use of such epitope-tagged receptors has provided means to employ 
immunocytochemical and biochemical techniques to facilitate the cellular and molecular 
studies of these GPCRs.  Using such approaches, it was initially described that the rat mu 
opioid receptor, when stably expressed in HEK293 cells, does not internalise upon treatment 
with morphine, unlike the effects of enkephalin analogues such as  [D-Ala2, N-MePhe4, Gly-
ol5]-enkephalin (DAMGO) [14]. Similarly, it was observed that the alkaloid etorphine and 
enkephalin peptides promoted rapid endocytosis of the murine mu opioid and delta opioid 
receptors expressed in HEK293 cells, whereas morphine did not facilitate the internalisation 
of these opioid receptors, even at concentrations that strongly inhibited adenylyl cyclase 
activity [15]. These reports were the first to demonstrate that rapid internalisation of the mu 
opioid receptor is facilitated by agonist activation, as had been described earlier for the β2-
adrenoceptor. However, occupancy and activation of the mu opioid receptor by certain 
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agonists, such as morphine, was insufficient to trigger the endocytic process. This feature of 
morphine seems not to be related to its chemical class because other alkaloid opioids such as 
etorphine and methadone do promote mu opioid receptor internalisation [15]. This agonist-
dependency of mu opioid receptor internalisation is not a feature limited to heterologous 
expression systems. Simultaneous studies employing guinea pig myenteric motor neurons 
reported the first demonstration of rapid and agonist-selective endocytosis in cells that express 
mu opioid receptors endogenously. As in HEK293 cells, morphine, unlike etorphine, was 
completely ineffective in inducing mu opioid receptor internalisation [16]. Since these initial 
investigations, subsequent research on the inability of morphine to initiate internalisation of 
the mu opioid receptor has been focussed predominantly on the following questions: 1) Is 
there a correlation between agonist efficacy to activate the mu opioid receptor and capacity to 
facilitate receptor endocytosis? 2) What are the defining elements of the receptor protein 
structure that makes it reluctant to internalise in response to morphine? 3) Which proteins of 
the GPCR signalling machinery participate in mu receptor endocytosis and how might they 
facilitate endocytosis to morphine? 4) Is there any relationship between the lack of mu 
receptor internalisation and the development of tolerance and dependence after chronic 
morphine treatment? These issues will be considered in turn.  
 
1. Agonist efficacy and mu opioid receptor endocytosis 
Mu opioid receptors exert their actions by coupling preferentially to pertussis toxin-sensitive, 
heterotrimeric Gi/Go G proteins. After their dissociation, the Gα and Gβγ protein subunits 
regulate distinct effector systems, resulting in the inhibition of adenylyl cyclases, inhibition of 
voltage-gated calcium channels, stimulation of G protein-activated inwardly rectifying 
potassium channels (GIRKs) and stimulation of phospholipase Cβ (PLCβ) [1]. The initial 
characterisation of mu opioid receptors expressed in HEK293 cells [14, 15] showed that 
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effective inhibition of forskolin-stimulated adenylyl cyclase activity by morphine was not 
accompanied by receptor internalisation. These results led to the hypothesis that cell 
signalling and the endocytosis of mu opioid receptors in response to morphine were two 
independent processes.  Similarly, observations obtained with a mutant of the rat mu opioid 
receptor, in which much of the intracellular C-terminal tail was truncated prior to stable 
expression in HEK293 cells [17] indicated that this form of the receptor was able to 
internalise constitutively (i.e. in the absence of an agonist ligand) and to recycle. However, 
this was not associated with G protein activation as no increase in the binding of the 
nucleotide [35S]GTPγS was produced. A further, more comprehensive, study was performed 
in both living animals and in HEK293 cells stably expressing the mu opioid receptor [18]. 
Brain tissue from animals treated with effective analgesic doses of etorphine and morphine 
were analysed by microscopy and specific antibodies against mu opioid receptors. Receptors 
in neuronal cells from animals treated with etorphine were distributed mainly in intracellular 
pools, whereas in cells from animals treated with morphine the receptor was not internalised. 
In addition, the same authors assessed a range of different opioid drugs used in clinical 
practise in a cell line stably expressing the mouse mu opioid receptor and examined 
internalisation and adenylyl cyclase inhibition. They observed that effects on internalisation 
of individual ligands were not correlated with their potencies for receptor activation [18]. 
Another study performed in cultures of rat hippocampal neurons expressing a transfected, 
modified version of mu opioid receptor tagged at the C-terminus with the fluorescent protein 
YFP compared the internalisation promoted by three different agonists, DAMGO, methadone 
and morphine, with their capacity to induce tolerance in blocking inhibitory transmission and 
inhibiting voltage gated calcium channels [19]. DAMGO and methadone facilitated the 
internalisation of this receptor construct in cultured neurons, whereas morphine produced 
internalisation much more slowly, even after over-expressing β-arrestin-2 in the same cells. 
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By contrast, the three opioid agonists were equi-effective in inducing tolerance, 
demonstrating that morphine-induced tolerance in this experimental model was not 
necessarily accompanied by receptor endocytosis. Other investigations performed in AtT20 
cells stably expressing the mouse mu opioid receptor compared DAMGO, morphine, 
methadone and pentazocine in regard of their efficacy to activate G proteins by monitoring 
inhibition of calcium channel currents and in their production of rapid, homologous 
desensitisation to inhibit these calcium channels. In addition, these functional parameters 
were compared with the ability of the agonists to promote receptor internalisation [20]. A 
similar rank order of these agonists was observed for their relative efficacies to inhibit 
calcium channel currents and to generate rapid desensitisation. However, the rank order for 
the same agonists for internalising the receptor was different. In this experimental model, the 
efficacy of opioids to produce activation of G proteins and rapid desensitisation was distinct 
from their capacity to internalise mu opioid receptors. Another important result from this 
study was that morphine, despite not internalising mu opioid receptors, produced rapid 
homologous desensitisation as assessed via inhibition of calcium channel currents. This dis-
association between the capacity of opioid agonists to desensitise and internalise mu opioid 
receptor has not always been observed, however. Work conducted in rat locus coeruleus 
neurons and in HEK293 cells stably expressing rat mu opioid receptors resulted in opposite 
observations and conclusions [21]. Herein, activation of potassium channels was assessed for 
either peptide or alkaloid opioid agonists. The compounds presented distinct rank-order when 
comparing the magnitude of hyperpolarisation and the ability to cause homologous 
desensitisation. Moreover, the capacity of these agonists to cause receptor endocytosis in 
HEK293 cells correlated with the degree of desensitisation in locus coeruleus, suggesting that 
these processes might be linked and that agonist efficacy was not a predictor of the capacity 
of a particular agonist to cause mu opioid receptor desensitisation and/or internalisation. The 
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basis of the discrepancies between these two reports remain unclear but may be due to the 
differences in the experimental models used, in terms of the functional assay considered 
(activation of GIRKs versus inhibition of calcium channel currents), the host cell lines 
(HEK293 versus AtT20 cells) or the mu opioid receptor orthologue studied (rat versus 
mouse). Further investigations conducted in AtT20 cells expressing a GFP-tagged version of 
rat mu opioid receptor demonstrated that receptor uncoupling from G proteins is a GRK-
dependent process and requires the threonine residue at position 180 [22]. Substitution of 
threonine 180 by alanine, however, did not inhibit receptor internalisation, suggesting that 
endocytosis was controlled by a non GRK-dependent mechanism in AtT20 cells. There is 
further evidence supporting the hypothesis that mu opioid receptor rapid desensitisation and 
internalisation are independent processes. For example, in a study performed in primary 
cultured neurons from mouse locus coeruleus, where fluorescent peptides were used to assess 
mu opioid receptor activation, desensitisation and internalisation, it was observed that 
desensitisation and recovery were not altered after blocking receptor internalisation using 
concavalin A [23].    
One of the most elegant demonstrations of the lack of association between agonist efficacy 
and capacity to induce receptor endocytosis is the experiments reported by Whistler and 
collaborators using a chimeric mutant of the mu opioid receptor [24]. These studies were 
performed in HEK293 cells stably expressing either the wild type murine mu opioid receptor 
or a mu-delta opioid receptor chimera. This receptor mutant, described initially by Afify and 
collaborators [25], was generated by exchanging the C-terminal tail between mu and delta 
opioid receptors. Morphine, unlike other alkaloid agonists and enkephalin analogues, failed to 
promote either mu or delta opioid receptor endocytosis.  However, the chimeric form of the 
mu opioid receptor containing the C-terminus of the delta opioid receptor, whilst conserving 
the pharmacological profile of morphine in terms of potency and efficacy, demonstrated 
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strong internalisation upon exposure to morphine. After transient expression of GIRK 
channels in the same cells, different agonists were assessed for stimulation of potassium 
currents in parallel with internalisation experiments, explored using both 
immunocytochemistry and a biotinylation protection assay. Morphine and DAMGO were 
equi-effective in stimulating potassium currents through either mu or mu-delta opioid 
receptors whereas, as described earlier, morphine failed to internalise mu opioid receptors. 
These studies indicate a key role for the receptor C-terminal tail in defining internalisation 
(see also section 2) but not the relative functional activity of the agonists. Similar 
internalisation data were generated in cultured neurons transfected with the same chimeric 
receptor [24], thus excluding the possibility of artifactual consequences reflecting the use of 
HEK293 cells. Although it has been suggested that the poor capacity in many settings of 
morphine to cause internalisation of the mu receptor might simply reflect the partial agonist 
nature of this ligand, this is clearly too simple a view to sustain further support.  
This lack of correlation between agonist activity/efficacy and capacity to promote receptor 
endocytosis inspired Whistler and colleagues to propose the RAVE hypothesis [24]. RAVE is 
the acronym for Receptor Activity Versus Endocytosis, and is a ratio that considers for a 
particular drug agonist efficacy in relation to its capability to induce receptor endocytosis. For 
instance, if we consider DAMGO and morphine acting at the mu opioid receptor, both 
agonists display similar efficacy to stimulate signalling processes in many settings. However, 
the facilitation of receptor endocytosis by DAMGO is much more extensive than morphine. 
This defines that the “RAVE index” for DAMGO is lower than for morphine. The same is 
true for other alkaloid agonists that promote mu receptor internalisation, such as methadone 
and etorphine.  Mu opioid receptors, as many other GPCRs, generally recycle to the plasma 
membrane after endocytosis [7], where they will be ready again to be activated by the agonist. 
The absence of receptor internalisation after agonist binding might, therefore, be anticipated 
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to cause a deficiency in receptor desensitisation-resensitisation processes and, as a result, 
aberrant continuous signalling, resulting in extensive and diverse cellular alterations. The 
development of tolerance and dependence observed for some opioid drugs, such as morphine, 
following chronic treatment could be the physiological consequence of these cellular 
alterations. According to this hypothesis, it could be predicted that opioid agonists presenting 
a high “RAVE index” would generate stronger levels of tolerance and dependence than those 
with a lower ratio and several recent investigations have attempted to validate this hypothesis 
in physiological models of opioid analgesia (see section 4).  
 
2. Key elements of mu opioid receptor structure implicated in endocytosis 
As detailed earlier [24], it appears that the C-terminal tail of the mu receptor is a key 
component of its primary structure involved in receptor endocytosis. Initial experiments 
conducted in HEK293 cells described a mutant form of the rat mu receptor lacking most of 
the intracellular C-terminal tail that displayed constitutive internalisation and recycling [17]. 
Splice variation in the C-terminal tail of mu receptors is common, and the range and extent of 
variation is species dependent [26-28]. Characterisation in HEK293 cells of two splice 
isoforms of the rat mu receptor that vary only in the length of the C-terminal tail, indicated 
that the shorter isoform desensitised at a slower rate and resensitised more rapidly than the 
longer isoform when inhibition of intracellular levels of cAMP after stimulation with 
DAMGO was assessed [29]. Receptor internalisation studies also revealed that the shorter 
isoform endocytosed faster and recycled more rapidly than the longer isoform [29]. Similar 
studies have been performed with C-terminal splice variants of the mouse mu receptor stably 
expressed in HEK293 cells [30]. The MOR1 and MOR1C isoforms were phosphorylated, 
internalised and down-regulated when stimulated with DAMGO but not in response to 
morphine. By contrast, the MOR1D and MOR1E splice variants showed similar levels of 
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phosphorylation, internalisation and down-regulation in response to both DAMGO and 
morphine whilst functional assays measuring inhibition of intracellular cAMP accumulation 
showed the same desensitisation and resensitisation ratio for DAMGO for each of the four 
variants, whilst MOR1 and MOR1C desensitised more rapidly and did not resensitise after 
treatment with morphine. Splice variants of the rat mu receptor have been quantified by RT-
PCR in different brain areas [26], and the three most abundant, i.e. MOR1, MOR1A and 
MOR1B, were expressed in HEK293 cells together with GIRK channels to assess their 
regulation. Morphine induced rapid desensitisation for each of these three isoforms whereas 
DAMGO produced a slower rate of desensitisation via MOR1B. Furthermore, over-
expression of a dominant negative mutant of GRK2 demonstrated that the rate of 
desensitisation of MOR1 and MOR1A was independent of the agonist employed, whilst for 
MOR1B this was not true. Another comprehensive study generated point mutations, 
individually or in combination, of 12 Ser/Thr residues to Ala in the C-terminal tail of the rat 
mu receptor [31]. Three of these residues (Ser363, Thr370 and Ser375) were identified as 
phosphorylation sites and the internalisation of these mutants in response to DAMGO was 
explored. The Ser375Ala substitution displayed a reduced extent of internalisation, whilst the 
Ser363Ala and Thr370Ala substitutions showed significant increases in receptor internalisation 
kinetics. Although all of the above studies were performed in heterologous expression 
systems, neurons from mice treated intracerebroventricularly with DAMGO and morphine 
[32] have been examined by microscopy using antibodies reportedly selective for two MOP 
receptor splice variants (MOR-1 and MOR-1C). The MOR-1 variant internalised in response 
to DAMGO but not to morphine whereas MOR-1C internalised in response to both ligands. 
Regardless of whether receptor desensitisation and internalisation are correlated or 
independent processes, the C-terminal intracellular domain is considered to be the region of 
receptor structure essential for these cellular events. This is not surprising as the receptor C-
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terminus is a domain where many amino acids susceptible to be phosphorylated by different 
protein kinases are located. Particularly for the rat mu receptor, Ser375 has been described as a 
key residue homologously phosphorylated after receptor stimulation with either DAMGO or 
morphine [33]. Interestingly, DAMGO-stimulated receptors dephosphorylated and then 
resensitised more rapidly, compared to morphine-occupied receptors, which persisted in the 
plasma membrane in the phosphorylated state for a longer period of time. Moreover, although 
not absolutely required for some specific receptors [6], the interaction of phosphorylated 
GPCRs with arrestins to initiate the endocytic process often occurs through the receptor C-
terminal intracellular domain [34]. Nevertheless, a recent report [35] describes mu receptor 
variants outwith the C-terminus that display differences in signalling and internalisation.  
These modifications are naturally occurring mutations or single nucleotide polymorphisms 
(SNP) of the human mu receptor. Two different mu receptors SNPs, containing either 
Leu85Ile or Arg181Cys variants, were expressed in HEK293 cells and characterised by 
functional and internalisation assays. Both variants displayed distinct behaviours from the 
wild type receptor. The Leu85Ile mu receptor was endocytosed in response to morphine as 
robustly as with DAMGO, whereas the Arg181Cys variant lacked both signalling and 
internalisation in response to DAMGO. 
 
3. The role of other proteins in mu receptor endocytosis in response to opioid agonists 
There are many proteins of the cell endocytic machinery involved in the internalisation of 
GPCRs after their stimulation by an agonist [6]. As noted earlier, following agonist binding, 
conformational changes in the receptor promote interaction with GRKs. There are seven GRK 
subtypes, differentiated by their cell type expression as well as their intracellular distribution 
[36]. Some, such as GRK2 and GRK3, are cytosolic proteins that migrate to the plasma 
membrane upon GPCR activation. GRK-mediated phosphorylation and subsequent 
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interactions with arrestins abrogates receptor coupling to G proteins and constitutes, at the 
molecular and cellular level, the desensitisation process of GPCRs [37]. In addition, arrestins 
trigger endocytosis by recruiting other proteins, such as clathrin and AP-2, which facilitate the 
formation of clathrin-coated vesicles. Finally, the GTPase dynamin completes the formation 
of vesicles and hence sequesters receptors inside endosomes [7]. 
Initial experiments in HEK293 cells expressing the murine mu receptor demonstrated that 
internalisation promoted by etorphine and DAMGO was a dynamin-dependent process [38]. 
As noted earlier, morphine failed to induce MOP receptor endocytosis. However, following 
over-expression of a β-arrestin or GRK2 in these cells, morphine promoted rapid endocytosis 
of mu receptors. In addition, over-expression of β-arrestin facilitated the uncoupling of mu 
receptors from G proteins in response to morphine. Similar studies using rat mu receptor, 
expressed transiently in HEK293 cells, noted that over-expression of GRK2 and β-arrestin-1 
enhanced receptor internalisation by etorphine and promoted receptor internalisation by 
morphine [39]. However, over-expression of β-arrestin-1 did not facilitate morphine-mediated 
internalisation of mu receptor whereas over-expression of GRK2 or β-arrestin 1 plus GRK2 
facilitated receptor endocytosis to morphine. Additionally, over-expression of GRK2 
enhanced mu receptor phosphorylation in response to morphine. Equivalent results were 
observed in the neuronal cell model, NG108-15, transfected to transiently express rat mu 
receptor tagged with the fluorescent protein eGFP [40]. By contrast, over-expression of 
phosducin, a regulator of G protein signalling, blocked the internalisation of mu receptor in 
response to etorphine, an effect that was reversed by the simultaneous co-expression of 
phosducin and β-arrestin-1. As in other cell lines, morphine failed to internalise mu receptors 
expressed in NG108-15 cells. However, in agreement with the above, over-expression of β-
arrestin-1 facilitated mu receptor internalisation by morphine in these cells. In more native 
systems, including enteric neurons of the guinea pig [41], it was observed that endocytosis of 
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endogenous mu receptors by DAMGO and etorphine was clathrin-mediated and that the 
receptor recycled following endosomal acidification. Following recycling, the mu receptors 
were again functional.  
Overall, it is reasonable to conclude that mu receptor internalisation is dynamin-dependent 
and both GRKs and arrestins are cytosolic protein determinants of the endocytic process. 
Nevertheless, it is important to note that, in the majority of cases, conclusions have been 
derived via either over-expression of these proteins or of equivalent dominant negative 
mutants. Further studies, using for example interference mRNA technologies to silence the 
endogenous expression of these proteins, would assist in corroborating their role in mu 
receptor endocytosis. An important issue to consider is why morphine does not cause 
internalisation of mu receptors in the same cells in which other opioid agonists do and why 
this deficiency in receptor internalisation in response to morphine may be compensated by 
overexpression of GRKs and/or arrestins. One possible reason is that the conformational 
change promoted in the mu receptor by morphine is not sufficient to activate and recruit 
GRKs and arrestins in the surrounding plasma membrane area where the stimulated receptors 
are located. Over-expression of these cytosolic proteins would provide a higher probability of 
their interaction with morphine-occupied mu receptors. In such a situation, morphine would 
be expected to produce a specific homologous desensitisation of mu receptors because it 
would be dependent on the level of GRK and/or arrestin expressions in cells. However, this is 
not the case for all opioid agonists that fail to cause internalisation of mu receptor. It has been 
reported recently that a chemical derivate of salvinorin A named herkinorin is a novel, 
selective agonist for the mu receptor [42]. Experiments using the mouse mu receptor stably 
expressed in HEK293 cells resulted in an absence of both receptor internalisation and 
recruitment of β-arrestin 2 to the plasma membrane after stimulation with herkinorin. Over-
expression of GRK2 facilitated mu receptor endocytosis and β-arrestin 2 mobilisation by 
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morphine, but herkinorin still failed to produce substantial changes in the trafficking 
properties of the receptor. This did not reflect the lack of agonist activity of herkinorin 
because ERK1/2 phosphorylation experiments resulted in similar maximal responses to 
DAMGO, morphine and herkinorin. The results with herkinorin suggest that hypotheses to 
explain the absence of mu receptor internalisation by morphine cannot be directly 
extrapolated to other opioid agonists.  Nevertheless, other investigations have corroborated 
this hypothesis for morphine in more native models. For example in nucleus accumbens 
transfected by injection of a viral gene transfer vector encoding either the wild type mu 
receptor or the chimeric mu-delta receptor [43]. Interestingly, there can also be differences in 
effects of morphine on endogenous mu receptors in distinct compartments of the same cell.  
In cell bodies of the nucleus accumbens morphine failed to internalise mu receptors, whereas 
in neuronal processes morphine produced a rapid and prominent effect on the distribution of 
mu receptor [43].  This may reflect heterogeneous intracellular distribution of other proteins 
involved in the endocytic process, such as GRKs and arrestins, but further work is required to 
assess this directly. In a similar study by the same team using primary cultures of rat striatal 
neurons [44], morphine induced the redistribution of both endogenous and recombinant mu 
receptors. Morphine and DAMGO internalised the receptors to the same extent and in both 
cases these effects were inhibited by the over-expression of a dominant negative mutant of β-
arrestin 2. Although endogenous expression levels of β-arrestin1/2, as assessed by 
immunoblotting, were equivalent in cultured striatal neurons and HEK293 cells, substantial 
differences were found in GRK2 expression, with GRK2 being expressed at substantially 
higher levels in striatal neurons than in HEK293 cells.   
Regulators of G-protein signalling (RGS) is other family of proteins involved in GPCR 
function, including mu opioid receptors. Receptor signalling processes are modulated 
negatively by RGS proteins as these facilitate the hydrolysis of GTP associated with Gα 
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subunits and therefore interrupt activation of different cellular effectors. RGS9-2 is a brain-
specific splice variant of the RGS9 subtype expressed in neural regions associated with 
nociception and where mu opioid receptors are expressed. RGS9-2 is particularly highly 
enriched in striatum and, although expressed at substantially lower levels in PAG and spinal 
cord, is present [45]. In vitro experiments performed with mouse PAG membranes showed 
that mu opioid receptor could be co-immunoprecipitated with α-subunits of Gi/o/z/q/11 proteins, 
Gβ1/2 subunits as well as both RGS9-2 and its partner protein Gβ5 [46]. These interactions 
were modulated by morphine since 30 minutes and 3 hours after drug administration the co-
immunoprecipitation of mu receptor-Gα subunit was reduced up to 50% whilst the interaction 
Gα-RGS9-2 was conversely increased. Further studies have examined RGS9-2 involvement 
in mu opioid receptor endocytosis and signalling [47]. Mouse embryonic fibroblasts (MEF) 
from both wild type and RGS9-2 knock out animals were transiently transfected with mu 
receptor and receptor internalisation in response to morphine was explored. Receptors 
expressed in wild type MEF were internalised after 30 minutes of morphine treatment 
whereas in RGS-2 KO MEF receptor endocytosis occurred much more rapidly. Equivalent 
results were obtained in PC12 cells transiently expressing RGS9-2 and mu opioid receptors, 
where RGS9-2 over-expression delayed DAMGO-induced receptor internalisation. 
Furthermore, and in agreement with previous observations, morphine treatment enhanced 
interactions between mu receptor and RGS9-2 assessed by co-immunoprecipitation in PC12 
cells and promoted the association of RGS9-2 with β-arrestin 2. Moreover, over-expression of 
RGS9-2 prevented phosphorylation of extracellular signal-regulated kinase (ERK) mediated 
by the mu opioid receptor. Overall, these results indicated that RGS9-2 negatively modulates 
mu opioid receptor signalling and the rate of receptor endocytosis [47]. Some aspects of these 
studies are surprising as, in general, the internalisation of many GPCRs does not require 
signal generation or even the expression of G protein. Thus, further work is required to define 
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if the reported effects of RGS9-2 in these studies is due to the regulation of the G protein 
GTPase cycle or might reflect that many RGS protein also have direct interactions with other 
signalling proteins, and in some cases, can interact directly with GPCRs. RGS14 is another 
RGS subtype that has been linked to mu opioid receptor function. Silencing of RGS14 
expression in mouse PAG neurons enhanced mu receptor phosphorylation at Ser375 in 
response to morphine [48]. Subsequently the receptors were internalised and recycled to the 
plasma membrane. Additionally, RGS14 prevented GRK-mediated phosphorylation of mu 
receptors activated by morphine and, consequently receptor endocytosis mediated by β-
arrestin 2. 
There are other proteins, such as phospholipase D2 (PLD2), that are able to modulate the 
endocytic process by interacting directly with mu receptors [49]. HEK293 cells stably 
expressing the rat MOR1 mu receptor and human PLD2 showed receptor internalisation 
accompanied by an increase in PLD2 activity after treatment with DAMGO. On the other 
hand, morphine failed either to induce PLD2 activation or to produce receptor endocytosis. 
However, phorbol ester activation of PLD2 facilitated the internalisation of mu receptor by 
both DAMGO and morphine. Furthermore, inhibition of PLD2 by 1-butanol or PLD2 
dominant-negative mutants prevented agonist-mediated endocytosis of mu receptors, defining 
the participation of PLD2 in this process. 
Not surprisingly, other GPCRs are able to modulate mu opioid receptor endocytosis. The first 
demonstration of a receptor facilitating mu receptor internalisation reflected a potential role 
for mu opioid receptor dimerisation or oligomerisation [50]. These authors demonstrated, 
firstly in HEK293 cells, that the chimeric mu-delta receptor construct previously described 
[24] promoted intracellular accumulation of wild type mu receptor after treatment with 
morphine when the two forms were co-expressed. Furthermore, equivalent results were 
obtained in cultured neurons transfected with the same mu opioid receptor constructs. Most 
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interestingly, sub-effective doses of DAMGO, i.e. doses that did not directly produce mu 
opioid receptor internalisation, promoted wild type mu receptor internalisation in response by 
morphine, again suggesting a potential involvement of receptor dimerisation/oligomerisation 
in this process although the molecular contribution of DAMGO to this process remains 
uncertain. These results were extended in studies performed in living animals by exploring the 
development of tolerance to chronic treatment with morphine. Sub-effective doses of 
DAMGO in combination with morphine resulted in a more attenuated development of 
tolerance than treatments using morphine alone. In addition, examination by immuno-
histochemistry of brain cells revealed that animals treated with DAMGO plus morphine 
showed mu opioid receptors in intracellular compartments whilst the animals treated with 
morphine alone did not.  Recently, modulation of mu opioid receptor internalisation by 
heteromerisation with other GPCRs, including the metabotropic mGluR5 has also been 
described [51]. When rat mu opioid and mGluR5 receptors were co-expressed in HEK293 
cells, the non-competitive mGluR5 antagonist MPEP decreased DAMGO-induced mu 
receptor phosphorylation, internalisation and desensitisation, whereas non-selective, 
competitive mGluR5 agonists or antagonists had no effect on this process. Moreover, 
immunoprecipitation experiments demonstrated an increase in the extent of interaction 
between the receptors in samples from cells treated with MPEP. Collectively these results 
suggest a possible allosteric modulation of mGluR5 that affects agonist-induced MOP 
receptor signalling and regulation via receptor-receptor interactions [52]. Other studies report 
modulation of mu opioid receptor endocytosis by other GPCRs via mechanisms that do not 
involve receptor heteromerisation. This is the case of pharmacological interactions between 
co-expressed human serotonin 5-HT2A and mu opioid receptors [53]. By generating cell lines 
in which the 5-HT2A receptor was located at an inducible locus, whilst also constitutively 
expressing mu receptors, these authors demonstrated that treatment of cells expressing only 
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the mu receptor did not result in desensitisation, internalisation or down-regulation whilst, as 
anticipated, DAMGO treatment produced robust effects on each of these parameters. 
However, after induction of 5-HT2A receptor expression, treatment of the cells with a 
combination of morphine plus serotonin, but not serotonin alone, caused MOP receptor 
internalisation to a similar extent as observed for DAMGO. The use of a 5-HT2A receptor 
antagonist (mianserin), a Gq/11 uncoupling compound (YM254890) or a Protein Kinase C 
inhibitor (Ro318220), inhibited internalisation of the mu receptor promoted by the 
combination of morphine plus serotonin, demonstrating the involvement of 5-HT2A receptor 
signalling in this process. Although it could not be absolutely discarded, heteromerisation 
between 5-HT2A and mu receptors as a basis to explain these observations of facilitation was 
considered unlikely because the cellular distribution of the two receptors did not coincide; mu 
receptor was expressed predominantly at the plasma membrane whereas 5-HT2A receptors 
underwent constitutive internalisation and recycling and, at steady-state, were present 
predominantly in recycling endocytic vesicles [53]. Another recent report has described the 
regulation of mu receptor endocytosis and desensitisation by NK1 neurokinin receptors [54]. 
Mouse mu opioid and rat neurokinin 1 receptors were transiently expressed in both primary 
striatal and amygdala neurons and in the neuroblastoma 2A cell line. Each of these systems is 
unusual because morphine promotes endocytosis of mu receptors expressed alone. Following 
co-expression of mu and neurokinin 1 receptors, the activation of the neurokinin 1 receptor 
population with substance P inhibited mu receptor desensitisation and endocytosis. In 
addition, this heterologous pairing also resulted in a functionally significant attenuation of 
morphine-induced desensitisation of mu receptor signalling via adenylyl cyclases. Studies 
involving over-expression of β-arrestin 2-GFP and a neurokinin 1 receptor mutant unable to 
interact with β-arrestin2 indicated that the negative modulation of mu receptor endocytosis by 
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the neurokinin 1 receptor might be achieved by sequestering arrestins in endosomes and 
hence limited their availability to interact with the mu receptor [54].  
 
4. Endocytosis of mu opioid receptors and development of morphine tolerance and 
dependence in living animals 
Chronic treatment of experimental animals with morphine results in development of tolerance 
and dependence to this ligand. Morphine tolerance is manifest as the lost of effectiveness in 
nociception assays during the course of the sustained administration of an initially effective 
dose of the drug. In addition, chronic exposure to morphine also results in a dependence that 
is defined by the appearance of physical symptomatology after the abrupt withdrawal of the 
drug. Although both processes are the result of morphine action and consequently the result of 
mu opioid receptor activation, the cellular and molecular basis of each event is different.  In 
physiological terms, tolerance may be considered the result of deficient receptor 
resensitisation at the cellular level, whereas dependence is more related to changes that occur 
in diverse elements of the cell signalling machinery involved in receptor activation. The mu 
opioid receptor couples preferentially to Gαo/i Gprotein subunits and these inhibit the activity 
of adenylyl cyclases and hence reduce intracellular levels of cAMP. It has been noted for 
many receptors that couple to inhibitory Gαo/i G proteins that persistent receptor stimulation 
results in a paradoxical enhancement of adenylyl cyclase activity that increases the levels of 
accumulated cAMP when the action of the inhibitory receptor is terminated [55]. This 
adenylyl cyclase superactivation or supersensitisation is considered to be an adaptive cellular 
response to compensate for chronic inhibitory input. Adenylyl cyclase superactivation has 
been observed routinely after chronic stimulation of a number of GPCRs (for review see 
[55]), and in the case of morphine and the mu opioid receptor it is considered as one of the 
cellular hallmarks of dependence and withdrawal. As mentioned earlier, the replacement of 
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the C-terminal tail of the mu opioid receptor with the C-terminal tail of the delta opioid 
receptor generates a chimeric receptor that is endocytosed in response to morphine [24]. 
Additional studies conducted by the same authors [56], evaluated the induction of adenylyl 
cyclase superactivation by mu opioid receptor mutants expressed in HEK293 cells following 
chronic treatment with morphine. Mutant receptors that internalised in response to morphine 
generated a lower cAMP superactivation than the wild-type receptor. Conversely, a mutant 
form of the receptor that failed to induce GRK-mediated phosphorylation, arrestin recruitment 
or endocytosis in response to methadone resulted in a higher cAMP superactivation than the 
wild-type receptor following chronic treatment with this drug. Therefore, there appears to be a 
negative correlation between agonist facilitation of mu opioid receptor endocytosis and the 
generation of adenylyl cyclase superactivation. Nevertheless, other reports point to opposite 
conclusions. Studies with the rat mu opioid receptor expressed in HEK293 cells in a inducible 
manner [57] described that the magnitude of cAMP superactivation was dependent on mu 
receptor density, regardless the agonist used, and experiments using dynamin dominant-
negative mutants indicated that this process was not dependent on receptor internalisation. 
Furthermore, the specifics of cell surface location of mu opioid receptors may to be a 
determinant for adenylyl cyclase superactivation because after long term agonist treatments 
the mu receptor was reported to be located in lipid rafts. Similarly, experiments conducted in 
CHO cells stably expressing the human mu opioid receptor compared DAMGO (internalising 
ligand) with herkinorin (non-internalising ligand) in their ability to produce tolerance, 
desensitisation and up-regulation of the cAMP system [58]. That both agonists were 
equivalent in modulating these pharmacological parameters appears to exclude a direct 
relationship between mu receptor internalisation and the generation of cAMP superactivation. 
Overall, there is still considerable debate and controversy as to whether the production of 
adenylyl cyclase superactivation is a feature that distinguishes mu opioid agonists that are 
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poorly able to promote receptor internalisation.  Many of the key findings relate to 
heterologous expression systems by means in vitro experimental approaches. However, 
numerous investigations have been conducted to attempt to elucidate whether conditions that 
facilitate mu opioid receptor endocytosis by morphine in cellular experimental models may be 
translated to a reduction of the development of morphine tolerance and dependence in in vivo 
physiological models. In this regard, experiments in rats to assess the development of 
tolerance using equi-effective doses of three different opioid agonists showed that 
etonitazene, an agonist that promotes mu opioid receptor internalisation in HEK293 cells, 
developed less tolerance and lower sensitisation to  locomotor stimulants than morphine and 
buprenorphine, agonists that fail to promote receptor internalisation in heterologous 
expression systems [59]. Other investigations validated in living animals results obtained 
concurrently in heterologous expression systems. For example, the demonstration, as noted 
earlier, that mu opioid receptor endocytosis may be facilitated by receptor homo-
oligomerisation. Sub-effective doses of DAMGO in combination with morphine also inhibit 
the development of tolerance following chronic treatments as assessed in tail-flick 
nociception studies. This reduction in tolerance was accompanied by mu opioid receptor 
internalisation in neuronal cells [50]. These studies have been extended.  The combination of 
morphine with a small dose of methadone provided a “pharmacological cocktail” that 
preserved the full analgesic properties of morphine but were reported not to generate tolerance 
and dependence [60]. Initial experiments in HEK293 cells demonstrated that the mu opioid 
receptor internalised when treated with this drug combination and that this was accompanied 
by a reduction in cAMP superactivation compared to cells treated with morphine alone. 
Animals treated chronically with this “cocktail” presented considerably less tolerance in tail-
flick nociception assays together with a predominantly intracellular mu receptor distribution 
in neurons. In addition, this reduction in tolerance and dependence was associated with 
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prevention of the up-regulation of NMDA receptor subunits in some brain areas. Similar 
findings were obtained in experiments conducted in rats injected intrathecally with opioids 
and assessed for nociception and that subsequently used their spinal cords for 
immunohistological analysis [61]. The co-administration of sub-analgesic doses of either 
DAMGO or fentanyl with morphine resulted in potentiation of morphine analgesic effects and 
facilitated mu opioid receptor internalisation. Another significant validation in living animals 
of previous in vitro results was the use of genetically engineered mice expressing the mu-delta 
opioid receptor chimera described earlier [24]. These animals were treated chronically with 
either morphine or methadone and then examined for tolerance to antinociceptive responses in 
the hot-plate latency test and for naloxone precipitated withdrawal in parallel with wild-type 
littermates [62].  Methadone treatment resulted in no significant differences between the 
genotypes. However, the knock-in mice showed substantially reduced antinociceptive 
tolerance to morphine, together with reduced physical dependence assessed by scoring 
standard withdrawal behaviours including jumping, “wet dog” shakes, paw licks and paw 
tremors. Further studies employing these knock-in mice have explored a number of changes at 
the physiological level that have been implicated previously in the development of morphine 
tolerance and dependence, including adenylyl cyclase superactivation, alterations in NMDA 
and glucocorticoid  receptor levels and c-fos gene expression [63].  Chronic morphine 
treatment of wild type mice resulted in brain region-dependent superactivation of cAMP 
(striatum), reduction of NMDA subunits (NR1, NR2A and NR2B) in the PAG and up-
regulation of NR2B in thalamus, increase in glucocorticoid receptor protein level in PAG and 
thalamus and increase of c-fos expression in striatum. Conversely, none of these parameters 
were altered in the knock-in mice following morphine treatment. As mentioned earlier, in 
vitro experiments performed in different cell models defined involvement of proteins 
including the arrestins, GRKs and RGS in receptor endocytosis. The ablation of expression of 
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several of these proteins in genetic modified animals has been achieved. Such knock-out (KO) 
animals have become an essential group of experimental tools to elucidate the possible 
participation of arrestin, GRKs and RGS in physiological processes following mu opioid 
receptor activation in vivo.  For example, mice lacking expression of β-arrestin 2 exhibit a 
remarkable potentiation and prolongation of the analgesic effect of morphine, consistent with 
the concept that mu opioid receptor desensitisation was impaired in these animals [64]. This is 
despite radioligand binding assays showing no difference to wild type littermates in 
[3H]naloxone binding sites in all the brain regions examined. By contrast, DAMGO 
stimulated greater binding of [35S]GTPγS in membranes derived from β-arrestin 2 KO mice 
than those derived from wild-type littermates. Additional studies found that desensitisation of 
mu opioid receptors failed to occur after chronic morphine treatment of β-arrestin 2 KO mice 
[65] and these animals failed to develop antinociceptive tolerance. Nevertheless, chronic 
morphine-induced up regulation of adenylyl cyclase activity was not prevented. Interestingly, 
[35S]GTPγS binding assays performed in membranes from brain of wild-type mice pre-treated 
chronically with morphine showed a reduction of  DAMGO stimulation, whereas this was not 
observed in membranes from the β-arrestin 2 KO mice.  Other alterations observed in β-
arrestin 2 KO mice were attenuation of both respiratory depression and constipation caused 
by morphine treatment [66]. Unlike the case for β-arrestin 2, phenotypic characterisation of 
mice lacking individual GRK subtypes has not provided conclusive results in this regard. 
Studies conducted with GRK3 KO mice showed no differences in acute antinociceptive 
responses to either fentanyl or morphine [67]. However, in vivo experiments assessing 
electrophysiological response in hippocampus indicated that tolerance to fentanyl was 
blocked by GRK3 deletion. Another recent report describes the characterisation of GRK6 KO 
mice [68]. Over-expression of GRK6 in HEK293 cells transiently expressing mu opioid 
receptors facilitated morphine-induced β-arrestin 2 recruitment and mu receptor 
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internalisation, whilst acute morphine treatment of GRK6 KO mice induced greater locomotor 
activation but less constipation than in wild-type litter mates. Nevertheless, thermal 
antinociception, analgesic tolerance and physical dependence were not affected by ablation of 
the GRK6 gene. The important discrepancy found in this study between in vitro and in vivo 
results confirms the need for caution when interpreting and/or extrapolating observations 
from heterologous expression systems to physiological models. As mentioned earlier, RGS 
proteins play an important role in modulating mu opioid receptor signalling and endocytosis. 
Characterisation of RGS9 KO mice revealed that these animals displayed enhanced 
behavioural responses to acute and chronic morphine treatment [45]. These alterations 
included morphine analgesia with delayed tolerance that was accompanied by exacerbated 
signs of physical dependence and withdrawal [45].  Similarly, in vivo knock-down of RGS9-2 
expression in mice prevents morphine from altering the association between mu opioid 
receptors and G-proteins as well as the absence of development of tolerance [46]. As such, 
these authors concluded that the development of morphine tolerance was caused by the 
stabilisation and retention of mu receptor-activated Gα subunit complexes by RGS9-2. 
Further studies have been performed in mice in which levels of RGS4 could be controlled. 
Systemic injections of morphine induced comparable antinociceptive effects in wild type and 
RGS4 KO animals in the tail flick test as well as in the first reaction of the hot-plate test. 
Additionally, no difference between mutant and wild type mice was observed for somatic 
signs of abstinence to opioids [69]. A recent study employed both constitutive RGS4 KO 
mice, conditional nucleus accumbens-targeted RGS4 KO mice and mice overexpressing 
RGS4 in the nucleus accumbens [70]. However, results were difficult to interpret in relation 
to the actions of morphine since it appeared that in nucleus accumbens RGS4 acted as a 
negative regulator of morphine reward whereas in locus coeruleus RGS4 opposed the 
development of physical dependence by morphine. Thus, although RGS4 can act as a positive 
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modulator of opiate analgesics such as methadone and fentanyl, it may not affect either 
morphine analgesia or tolerance. 
 
Conclusions 
Although mu opioid receptors comply with general paradigms established for other GPCRs in 
terms of receptor desensitisation, internalisation and resensitisation, the initiation of these 
processes is dependent on the identity of the participating agonist. This has been examined 
most extensively for morphine, not least because of the widespread use of this drug as a 
remarkably effective analgesic.   In contrast to many other opioid alkaloids and enkephalins, 
morphine is frequently reported to be unable to promoter effective receptor internalisation 
despite displaying high agonist efficacy in many (but not all) assays. Because receptor 
internalisation is believed to be required to allow desensitised GPCRs to resensitise, 
hypotheses have been developed that suggest that the inability of morphine to promote 
receptor internalisation is causally linked to the development of tolerance to morphine over 
time and, potentially, to the symptoms of physical dependence. However, in certain cells and 
tissues, morphine is able to stimulate mu receptor internalisation from the cell surface, either 
when used alone or in combination with other receptor ligands (Table 1) . Figure 1 
summarises situations in which morphine does promote internalisation of mu receptors 
expressed in heterologous systems. It is now widely accepted that GPCRs are organised as 
dimers or higher order oligomers. This structural feature has been promulgated as a means to 
explain the endocytosis of morphine-occupied mu receptors by sub-effective doses of other 
opioid agonists (Figure 1A). Other possibilities include structural changes in relation to the 
protomer or the primary structure of the receptor (Figure 1B), and such effects may be related 
to the expression pattern of particular splice variants or, potentially in man, to particular 
polymorphisms. Among the most compelling sets of observations to correlate the generally 
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poor ability of morphine to promote mu receptor internalisation with tolerance and/or physical 
dependence are studies that have employed a chimeric mu-delta receptor in which the C-
terminal tail of the mu receptor was replaced with the equivalent region of the delta receptor. 
Initially in heterologous cells systems, and more recently in transgenic animals, this chimeric 
receptor has been used to link morphine tolerance with the lack of capacity of the mu receptor 
to internalise.  Even in model systems, alterations in the expression level of other proteins, 
including GRKs, arrestins and RGS proteins, can have dramatic effects on the morphine-
mediated regulation of mu receptor function (Figure 1C). Such observations require further 
analysis in animal models, but once again, transgenic and knock-out lines have begun to 
illuminate this issue.  Finally, activation of signalling cascades by other GPCRs co-expressed 
with mu opioid receptors may also facilitate their internalisation after morphine activation 
(Figure 1D). If such studies are translated to animal models and validate the link between the 
capacity of morphine-occupied mu receptors to internalise and the development of tolerance 
and dependence, they also suggest simple pharmacological strategies to limit the development 
of tolerance. Certainly, results obtained in vitro related to the protein structure of mu receptors 
(see Figure 1A and Figure 1B), have been largely confirmed in living animals; where 
chronic treatment with morphine that results in receptor internalisation in neural cells is 
generally accompanied by a substantial reduction of the development of morphine tolerance 
and dependence, suggesting an association between, but remains far from defining a causal 
link between, the two pharmacological events. Further results from in vivo experiments with 
animals lacking expression of proteins involved in mu receptor internalisation have so far 
resulted in uncertain conclusions. Mice devoid of either β-arrestin 2 or RGS9 protein 
expression develop reduced tolerance to antinociception following chronic treatment with 
morphine compared to their corresponding wild type littermates. However, these mutant 
animals do not present any significant alteration in the development of morphine dependence 
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and withdrawal. The divergence between these physiological consequences of prolonged 
morphine treatment suggests that they may be independent phenomena. As such, the 
correlation between mu receptor internalisation and desensitisation/resensitisation events at 
the cellular level, and the development of physical dependence probably occurs as the result 
of more complex and interconnected alterations, comprising multiple modifications. Further 
research needs to be conducted to elucidate the neuronal basis of morphine dependence before 
extrapolating results from single cell models to living animals. 
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PAG: periaqueductal grey; MEF: mouse embryonic fibroblasts; cAMP: cyclic adenosine 
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Table 1. Does morphine cause internalization of the mu opioid receptor? 
Cellular model Mu receptor Endocytosis in response to 
morphine 
References 
HEK293 rat, recombinant NO [14, 21, 39, 49] 
HEK293 mouse, 
recombinant 
NO [15, 24, 38, 42] 
HEK293 mouse MOR1, 
recombinant 
NO [30] 
HEK293 mouse MOR1C, 
recombinant  
NO [30] 
HEK293 mouse MOR1D, 
recombinant 
YES [30] 












AtT20 rat, recombinant NO [22] 




Neuroblastoma 2A mouse, 
recombinant 
YES [54] 
Myenteric motor neurons guinea pig, 
endogenous 
NO [16] 
Neurons from parietal cortex 
layer II 
rat, endogenous NO [18] 
Cultures of rat hippocampal 
neurons 
rat, YFP-tagged low rate [19] 





Neurons from lateral septum mouse MOR1, 
endogenous 
NO [32] 
Neurons from lateral septum mouse MOR1C, 
endogenous 
YES [32] 
Neurons from nucleus 
accumbens (cell bodies) 
rat, endogenous NO [43] 
Neurons from nucleus 
accumbens (neuronal 
processes) 
rat, endogenous YES [43] 





Neurons from PAG mouse, 
endogenous 
YES [48] 
















Figure 1. Experimental conditions that result in mu opioid receptor internalization in 
response to morphine 
Although in many situations morphine is unable to cause internalisation of mu opioid 
receptors to a significant extent, this is not an invariant observation. Situations in which 
morphine is able to promote such internalisation are illustrated. 
 A. Combinations of morphine with sub-effective doses of agonists that at higher 
concentrations are themselves able to stimulate receptor internalisation. This has been 
suggested to reflect aspects of mu receptor oligomerisation. B. Variations in the receptor C-
terminal tail of the mu receptor produced artificially by substitution with a distinct sequence 
(receptor chimeras) or in naturally occuring splice variants. C. Variation in the expression 
levels of polypeptides implicated in receptor signalling processes including arrestins, GRKs 
and RGS proteins. D. Activation of distinct signalling pathways by other receptors co-
expressed in the same cell as mu receptor. See text for further details. 
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